Synthetic lethality-based prediction of anti-SARS-CoV-2 targets
暂无分享,去创建一个
Lipika R. Pal | S. Chanda | E. Ruppin | J. Lee | L. Riva | Laura Martin-Sancho | N. Nair | K. Cheng | Xin Yin | S. Sinha | Fiorella Schischlik | Yuan Pu | J. S. Lee | Kuoyuan Cheng | Sanju Sinha
[1] Guohui Li,et al. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction , 2021, Signal Transduction and Targeted Therapy.
[2] Catharine I Paules,et al. COVID-19: The therapeutic landscape , 2021, Med.
[3] S. V. Ambi,et al. Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19 , 2021, Journal of medical virology.
[4] S. Adie,et al. Warfarin Dose Requirements in Adults Hospitalized With COVID-19 Infection: A Retrospective Case Series , 2021, Journal of pharmacy practice.
[5] Lipika R. Pal,et al. Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets , 2021, bioRxiv.
[6] N. Krogan,et al. Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses , 2020, Cell.
[7] Silva Kasela,et al. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells , 2020, Cell.
[8] Francisco J. Sánchez-Rivera,et al. Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks , 2020, Cell.
[9] E. Ruppin,et al. Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity , 2019, Science Advances.
[10] Elisabeth Mahase. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients , 2020, BMJ.
[11] V. Thiel,et al. Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.
[12] Peter C. DeWeirdt,et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection , 2020, Cell.
[13] R. Malekzadeh,et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.
[14] Lindsay N. Carpp,et al. Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality , 2020, bioRxiv.
[15] Wenwu Sun,et al. Serum Cystatin C and Coronavirus Disease 2019: A Potential Inflammatory Biomarker in Predicting Critical Illness and Mortality for Adult Patients , 2020, Mediators of inflammation.
[16] Francisco J. Sánchez-Rivera,et al. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks , 2020, bioRxiv.
[17] M. Borghesan,et al. Cellular senescence as a potential mediator of COVID‐19 severity in the elderly , 2020, Aging cell.
[18] Ruth Nussinov,et al. Artificial intelligence in COVID-19 drug repurposing , 2020, The Lancet Digital Health.
[19] Chenqi Xu,et al. Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction , 2020, bioRxiv.
[20] Paola Roncada,et al. Computational Immune Proteomics Approach to Target COVID-19 , 2020, Journal of proteome research.
[21] Michael DiCuccio,et al. Potential impact on coagulopathy of gene variants of coagulation related proteins that interact with SARS-CoV-2 , 2020, bioRxiv.
[22] P. Shi,et al. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age , 2020, PLoS biology.
[23] J. Walk,et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene polymorphism as determinant of differences in Covid-19-related disease severity , 2020, Medical Hypotheses.
[24] Arti T. Navare,et al. Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality , 2020, The Journal of cell biology.
[25] L. K. Sørensen,et al. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity , 2020, bioRxiv.
[26] S. M. Asdaq,et al. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review , 2020, Journal of Infection and Public Health.
[27] Eytan Ruppin,et al. Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning , 2020, Nature.
[28] V. Manolopoulos,et al. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies , 2020, European Journal of Clinical Pharmacology.
[29] Md. Abdullah-Al-Kamran Khan,et al. Perversely expressed long noncoding RNAs can alter host response and viral proliferation in SARS-CoV-2 infection , 2020, bioRxiv.
[30] Roland Eils,et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.
[31] M. Mann,et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV , 2020, Nature.
[32] James T. Gordy,et al. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development , 2020, Journal of Virology.
[33] Heidi Ledford. Coronavirus breakthrough: dexamethasone is first drug shown to save lives , 2020, Nature.
[34] F. Palombo,et al. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines , 2020, Journal of Translational Medicine.
[35] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[36] S. Ciesek,et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets , 2020, Nature.
[37] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[38] Lin Cheng,et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.
[39] P. Chapagain. Potential Role of Cellular Senescence on Coronavirus Infections , 2020 .
[40] Benjamin J. Polacco,et al. A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.
[41] Jean Thierry-Mieg,et al. Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions , 2020, bioRxiv.
[42] Colin Renfrew,et al. Phylogenetic network analysis of SARS-CoV-2 genomes , 2020, Proceedings of the National Academy of Sciences.
[43] F. Cheng,et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.
[44] F. Cheng,et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 , 2020, Cell Discovery.
[45] C. E.. WHO Coronavirus Disease (COVID-19) Dashboard , 2020 .
[46] Gennady Korotkevich,et al. Fast gene set enrichment analysis , 2019, bioRxiv.
[47] E. Ruppin,et al. Translational Reprogramming Marks Adaptation to Asparagine Restriction in Cancer , 2019, Nature Cell Biology.
[48] P. Bieniasz,et al. Genome-Wide Analysis of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) Binding to HIV-1 RNA Reveals a Key Role for hnRNP H1 in Alternative Viral mRNA Splicing , 2019, Journal of Virology.
[49] Paul J. Hoffman,et al. Comprehensive Integration of Single-Cell Data , 2018, Cell.
[50] P. Tamayo,et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. , 2019, Cancer cell.
[51] X. Ye,et al. CDC25B promotes influenza A virus replication by regulating the phosphorylation of nucleoprotein. , 2018, Virology.
[52] V. Popov,et al. Disruption of Phosphatidylserine Synthesis or Trafficking Reduces Infectivity of Ebola Virus. , 2018, The Journal of infectious diseases.
[53] Eytan Ruppin,et al. Harnessing synthetic lethality to predict the response to cancer treatment , 2018, Nature Communications.
[54] Thawfeek M. Varusai,et al. The Reactome Pathway Knowledgebase , 2017, Nucleic acids research.
[55] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[56] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[57] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[58] F. Osorio,et al. Cellular Poly(C) Binding Proteins 1 and 2 Interact with Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 1β and Support Viral Replication , 2011, Journal of Virology.
[59] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[60] J. Zavadil,et al. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy , 2008, The Journal of cell biology.
[61] Herbert Stegemann,et al. [The International Clinical Trials Registry Platform - ICTRP]. , 2007, Archivos latinoamericanos de nutricion.
[62] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[63] M. Boube,et al. Evidence for a Mediator of RNA Polymerase II Transcriptional Regulation Conserved from Yeast to Man , 2002, Cell.
[64] P. Hieter,et al. Establishing genetic interactions by a synthetic dosage lethality phenotype. , 1996, Genetics.